ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.
Hester Biosciences reported Q4 and FY26 results with consolidated revenue growth of 22% and substantial PAT increase. Strategy focuses on biologicals, capacity utilization, and African market expansion.
Hester Biosciences reported FY26 consolidated revenue of ₹3,325.99 Mn (₹332.60 Cr) and PAT of ₹57.48 Cr, focusing on global expansion in animal and poultry vaccines.
Hester Biosciences delivered a strong Q3 FY26 with standalone revenue up 12% and PAT up 140%, driven by robust Poultry Healthcare performance and operational leverage despite Animal Healthcare headwinds.